Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone

Ionis shares sold off after a “double-whammy” on July 9: eplontersen missed its Phase 3 primary endpoint in ATTR-CM and tominersen faced additional late-stage setbacks. While the financial hit was cushioned because both programs are partnered (eplontersen with AstraZeneca and tominersen with Roche), the article highlights stronger offsetting drivers, including Dawnzera (+63% sequential Q2 revenue) and Tryngolza (FDA approval in June; peak sales projected >$3B). Despite the sharp drop (>20% on July 9; ~30% below early-July peak), the author argues the sell-off is overdone and notes the consensus 12-month target is ~46% above the current share price.

Analysis

The market is likely conflating platform risk with partnered-program risk. For IONS, the immediate damage from the July readouts is mostly sentiment and headline beta; economically, the real question is whether sell-side estimates for the wholly owned portfolio need to move, and that answer depends far more on Dawnzera/Tryngolza adoption than on AZN/RHHBY trial outcomes.

Second-order, the partner structure actually caps near-term cash burn and reduces the chance of a balance-sheet event. If anything, the setback may improve strategic clarity: capital can stay concentrated on assets where Ionis captures full economics, which should matter more for a company trading at a growth multiple than for one dependent on uncertain milestones.

The contrarian miss is valuation timing: a de-rated 90x+ forward earnings name can be “cheap” on a 12-18 month earnings ramp and still stay range-bound for quarters if launch metrics don’t inflect. The next catalysts are not abstract; they are sequential prescription trends, ex-U.S. rollout data, payer access for Tryngolza, and the Sept. 22 zilganersen decision. Falsifiers are simple: if Dawnzera/Tryngolza growth decelerates materially over the next 1-2 quarters, or if zilganersen misses/gets delayed, the bear case regains control quickly.

Key Decisions for Investors

• Tactically buy IONS on weakness only if it holds post-event support and Dawnzera/Tryngolza prescription data stays sequentially positive; target 3-6 month horizon, with thesis invalidated by two straight quarters of launch deceleration.
• Use a small pair trade: long IONS / short XBI to isolate idiosyncratic recovery versus sector-wide biotech multiple compression; best entry is after volatility cools, not on the first rebound candle.
• Do not overtrade AZN or RHHBY on the headline alone; the economic hit to both partners looks too small to justify a standalone position, so treat them as neutral watch items unless management commentary signals broader pipeline reprioritization.
• Set an alert around the Sept. 22 zilganersen decision: approval would support the ‘fully owned assets drive value’ thesis, while a delay or CRL would likely keep the stock trapped despite the recent washout.
• For more conservative capital, wait for the next quarterly print and buy only if IONS can show that launch revenue is outpacing any modeled partner-program haircut; otherwise the stock may remain a value trap at a high multiple.